Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | POLR1A | O95602 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23866592 | 0.87 | MALT1 (0.46) | MALT1POLR1AIL1BALDH1A1P2RX7 | |
| SCHEMBL28650867 | 0.84 | MALT1 (0.44) | MALT1POLR1AIL1BALDH1A1P2RX7 | |
| SCHEMBL22519390 | 0.83 | MALT1 (0.43) | MALT1POLR1AIL1BALDH1A1P2RX7 | |
| SCHEMBL23866586 | 0.83 | MALT1 (0.43) | MALT1POLR1AIL1BALDH1A1P2RX7 | |
| SCHEMBL16791399 | 0.81 | MALT1 (0.43) | MALT1POLR1AIL1BALDH1A1P2RX7 | |
| SCHEMBL16083841 | 0.77 | GLA (0.39) | MALT1POLR1AALDH1A1TSHR | |
| SCHEMBL21610612 | 0.77 | MALT1 (0.37) | MALT1POLR1AIL1B | |
| SCHEMBL22010188 | 0.77 | MALT1 (0.37) | MALT1POLR1AIL1B | |
| SCHEMBL18256577 | 0.77 | MALT1 (0.37) | MALT1POLR1AIL1B | |
| SCHEMBL3069521 | 0.75 | PDK1 (0.35) | MALT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2024-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | MALT1 4480/4885POLR1A 4648/4885IL1B 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.